Traditional medicine, including the knowledge, skills and practices of holistic health care, exists in all cultures. It is based on indigenous theories, beliefs and experiences and is widely accepted for its role in health maintenance and the treatment of disease.Medicinal plants are the main ingred...ients of local medicines, but rapid urbanization is leading to the loss of many important plants and knowledge of their use. To help preserve this knowledge and recognize the importance of medicinal plants to health care systems, the WHO Regional Office for the Western Pacific has published a series of books on Medicinal Plants in China, the Republic of Korea, Viet Nam and the South Pacific. Medicinal Plants in Papua New Guinea is the fifth in this series. This book covers only a small proportion of the immense knowledge on traditional medicine, the plant species from which they are derived, the diseases they can treat and the parts of the plants to be used. The diverse cultures, languages and traditional practices of Papua New Guinea made this a particularly challenging project. But we believe the information and accompanying references can provide useful information for scientists, doctors and other users.
more
This fourth progress report November 2020 of the Global HIV Prevention Coalition reviews the progress in the 28 focus countries and complements the three previous progress reports. This report describes key developments in 2019–2020, identifies challenges and opportunities (including those associa...ted with the COVID-19 pandemic) and outlines priorities for the years ahead. It is divided into two main sections.
more
Each year since 2007, G-FINDER has provided policy-makers, donors, researchers and industry with a comprehensive analysis of global investment into research and development of new products to
prevent, diagnose, control or cure neglected diseases in low- and middle-income countries, making it the go...ld standard in tracking and reporting global funding for neglected disease R&D. This year’s report, the sixteenth overall, focuses on investments made in participants’ 2022 financial year (‘FY2022’) and, for the first time, adds comprehensive coverage of the product pipeline in each disease area.
more